Yearly Archives

2017

Maria Shriver’s Women’s Alzheimer’s Movement Partners with UCI MIND to Launch New Women-Focused Research Initiative

By In the News

More than 5.5 million Americans have Alzheimer’s disease. Two-thirds of them are women. The initiative will fund critical new women-based research. ORANGE COUNTY, Calif., (December 5, 2017) — A new partnership in Orange County, California is seeking answers to an essential question affecting global health: Why do more women get Alzheimer’s disease than men? UCI MIND, the University of California at Irvine’s Institute for Memory Impairments and Neurological Disorders, has announced a new research initiative in partnership with the Women’s Alzheimer’s Movement (WAM), a non-profit organization founded by former California First Lady Maria Shriver. The initiative, based on collaborative fundraising by both…

Read More

New study estimates 47 million Americans with preclinical Alzheimer’s disease

By In the News

In a study published today in Alzheimer’s & Dementia, UCI MIND faculty members Drs. Claudia Kawas and Maria Corrada, and colleagues at UCLA, reported the first estimates of preclinical Alzheimer’s disease (AD) and mild cognitive impairment (MCI) prevalence in the United States. According to the study, 2.4 million Americans are living with MCI due to AD (memory and other cognitive problems that do not meet criteria for dementia), and this number is expected to more than double by 2060. Moreover, the researchers estimated about 47 million Americans have preclinical AD, the presence of amyloid accumulation and/or neurodegeneration with no symptoms of memory…

Read More

Love, Marriage, and Alzheimer’s disease

By Commentary

Numerous studies have shown links between lifestyle factors and risk for Alzheimer’s disease and other dementias. A new assessment of available studies by investigators at University College in London examines one lifestyle factor, marriage, and finds that people with a spouse may be at decreased risk for Alzheimer’s disease and other dementias. In contrast, widows and people who have been single their whole lives may be at 20-40% increased risk. At UCI MIND, a variety of studies have explored the implications of spousal status on Alzheimer’s disease clinical trials. In particular, we’ve shown that people with Alzheimer’s who lack a…

Read More

MIND Matters, Fall 2017 Newsletter Now Available

By In the News

In this issue of MIND Matters: New grants awarded for cutting-edge science Interview with research participant, Jerry Leth Philanthropist highlight, Steve O’Leary Maria Shriver, celebrity honoree for 8th annual A December to Remember gala Donations to UCI MIND, September 2016 to September 2017 Read more here >

Read More

Perspectives on amyloid PET imaging

By Commentary, In the News

A new study published in JAMA Neurology explored participants’ perspectives on receiving amyloid PET scan results as part of an Alzheimer’s disease prevention clinical trial, the A4 study.  Participants at UCI MIND contributed to this important research, led by investigators at the University of Pennsylvania (read more about the study here). Amyloid PET is a biomarker test that could someday be used to identify people at increased risk for Alzheimer’s disease who may benefit from preventative or disease-delaying treatments. Biomarker testing such as amyloid PET is being used more and more in the research setting to identify participants appropriate for Alzheimer’s disease…

Read More

New UCI MIND animal model grant continues to draw attention

By In the News

UCI MIND co-director Frank LaFerla and Drs. Andrea Tenner, Kim Green, Grant MacGregor, Marcelo Wood, and David Baglietto-Vargas were awarded an $11.35 million grant from the National Institutes of Health to create the next generation of mouse models to study Alzheimer’s disease. The news released by UCI on October 9 continues to draw local media attention, featured in the LA Times/Daily Pilot and Newport Beach Patch this morning. UCI MIND is already home to the discovery of the first ever mouse model to develop both amyloid plaques and neurofibrillary tangles, the two hallmark pathologies of Alzheimer’s disease. Created by Dr….

Read More

UCI MIND Announces Maria Shriver as Celebrity Honoree for 8th Annual A December to Remember Gala

By Community Events, In the News

Maria Shriver, internationally renowned Alzheimer’s disease advocate, founder of The Women’s Alzheimer’s Movement, and former First Lady of California, will be honored at UCI MIND’s 8th annual A December to Remember gala on Saturday, December 2, 2017. “Maria Shriver is a champion for Alzheimer’s disease research and a voice of strength for many families and individuals who are suffering as a result of this disease,” says Dr. Joshua Grill, co-director of UCI MIND.  “We are proud to partner with Ms. Shriver and honor her important work that continues to shine a light on Alzheimer’s disease.” Shriver is the founder of…

Read More

Do you have questions about brain health and Alzheimer’s disease?

By Community Events

Join UCI MIND for its quarterly ASK THE DOC session where a panel of expert researchers and clinicians from UC Irvine will answer all of your most pressing questions! Date: Friday, October 27, 2017 Time: 10:00am-12:00pm Location: Alzheimer’s Association, Orange County Chapter (770 The City Drive South, 1st Floor, Orange 92868) Space is limited! Reserve your spot online bit.ly/UCIASKTHEDOC or by calling 800.272.3900. For questions, please contact 949.824.9475.

Read More

Research participant highlight – The Groves

By In the News

Marsha and Lionel Grove met in high school and have been married for over 50 years. Marsha graduated from UCLA and worked as a clinical laboratory scientist. Lionel is a USC alumnus and aerospace engineer. They now both participate in multiple studies at UCI MIND. What motivated you to participate in research at UCI MIND? Marsha: Our families are surrounded by Alzheimer’s disease. My sister and my mother both died with Alzheimer’s disease and Lionel has it in his family as well. We’ve experienced it first hand, so we want a cure to be found because we know just how…

Read More

Today is World Alzheimer’s Day!

By Commentary, Community Events

Today, September 21, is WORLD ALZHEIMER’S DAY! Our faculty and staff are spending this day, as they do every other day: In the laboratory performing cutting edge research with molecules, cells, and animal models to unlock the causes of Alzheimer’s disease and identify treatment targets Working with volunteer participants who have donated their time to help us better understand, diagnose, and treat Alzheimer’s disease through research Conducting clinical trials of promising therapies we hope will prevent, reduce, or reverse Alzheimer’s disease We hope today you will consider doing one or all of the following: ADVOCATE: Write to your local, state, or federal representative and communicate the need for increased funding for Alzheimer’s research and improved…

Read More

Blood test for Alzheimer’s disease? UCI MIND investigator, Dr. Mark Mapstone comments

By Commentary, In the News

By now, most Alzheimer’s researchers have seen the writing on the wall. If we are to realize successful treatments or even a cure for Alzheimer’s disease we must turn our attention from the study of patients who have already developed dementia to those who are in the earliest stages of the disease where presumably, the brain pathology is less extensive and possibly more receptive to intervention. This shift to studying preclinical disease will allow us to determine exactly what the earliest brain changes are and hopefully, develop means to treat, reverse, or even prevent these changes years before the symptoms…

Read More

FDA approves 23andMe for limited direct-to-consumer genetic risk testing

By Commentary, In the News

On April 6, the US Food and Drug Administration (FDA) partially reversed an earlier decision to halt direct-to-consumer (DTC) genetic testing by the company 23andMe, a personal genomics company based in Silicon Valley. The new decision approves the company to provide “genetic health risk reports” for 10 diseases, including 8 rare disorders—Alpha-1 Antitrypsin Deficiency, Celiac Disease, Early-Onset Primary Dystonia, Factor XI Deficiency, G6PD Deficiency, Gaucher Disease, Hereditary Hemochromatosis, and Hereditary Thrombophilia—and two common age-related neurological disorders—Parkinson’s disease and Alzheimer’s disease (AD). After age, the strongest risk factor for AD is genetics. The e4 allele of apolipoprotein E (APOE) is by…

Read More

Moving from the bedside to the desktop: Dr. Joshua Grill on employing analytics to further Alzheimer’s disease clinical trial designs

By In the News

Researchers spanning the nation are working to employ analytics to drive real changes for patients with various conditions. Joshua Grill, PhD, co-director of the Memory Impairments Neurological Disorders Institute at University of California Irvine, details how he and fellow researchers are using analytics systems for clinical trials on Alzheimer’s disease research and how data may shape trials moving forward…

Read More

A quick cure for Alzheimer’s?

By Commentary, In the News

Letters: A quick cure for Alzheimer’s? OC Register, March 29, 2017 Re: “Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery?” [News, March 5]: The Register recently reported on a local neurosurgeon who is injecting liposuctioned stem cell serum into the brain of a patient with Alzheimer’s disease for $10,000 per treatment. The neurosurgeon says the patient is improving…

Read More

UCI MIND faculty member, Dr. Claudia Kawas, awarded 2017 Potamkin Prize!

By In the News

American Academy of Neurology March 22, 2017 UCI MIND faculty member, Dr. Claudia Kawas, was announced as one of two recipients of the 2017 Potamkin Prize for her dementia research in The 90+ Study. Dr. Kawas has studied over 1,700 people over the age of 90, called the “oldest-old,” to understand more about brain aging and Alzheimer’s disease in the fastest-growing population segment throughout much of the world.  The $100,000 Potamkin Prize is an internationally-recognized achievement, sometimes referred to as the Nobel Prize of Alzheimer’s research. The other recipient, Dr. Kristine Yaffe from UCSF, focuses on modifiable risk factors for dementia, such as sleep disturbances and traumatic…

Read More

2017 Research Update: Intense Study, Rapid Progress

By Community Events

On March 14, UCI MIND’s community partner, Alzheimer’s Orange County, held their annual Research Update on Alzheimer’s disease at the Bowers Museum. The update was, for the second straight year, delivered by UCI MIND Co-Director, Dr. Joshua Grill. Dr. Grill described the current “state of the science” in understanding Alzheimer’s disease risk and way to lower that risk, new tools for use in diagnosing Alzheimer’s disease, and the critical pursuit of FDA-approved disease-modifying therapies. If you were unable to attend, you can watch a video here, courtesy of Alzheimer’s Orange County. If you’d like to attend a future lecture by UCI…

Read More

Hundreds attended UCI MIND’s “Ask the Doc” at South OC Senior Day on March 10th

By Community Events

Thank you to all who attended UCI MIND’s “Ask the Doc” this morning at South OC Senior Day provided by Senator Pat Bates and Assemblyman Bill Brough! Drs. Joshua Grill, Aimee Pierce, Mark Mapstone, and Kim Green answered many important and thoughtful questions from over 500 community members. Still have questions? Be sure to join us at our next “Ask the Doc,” May 2nd at Alzheimer’s Orange County. Register here>  

Read More